Current Rating and Its Significance
MarketsMOJO’s 'Buy' rating for Suraksha Diagnostic Ltd indicates a positive outlook on the stock, suggesting that investors may consider adding it to their portfolios. This recommendation is based on a comprehensive evaluation of the company’s quality, valuation, financial trend, and technical indicators. The rating was revised to 'Buy' from 'Hold' on 01 September 2026, reflecting an improvement in the company’s overall fundamentals and market positioning. Investors should note that while the rating change date is important, the detailed analysis below is grounded in the latest data available as of 05 October 2026.
Quality Assessment
As of 05 October 2026, Suraksha Diagnostic Ltd demonstrates a strong quality profile. The company holds a 'good' quality grade, underpinned by its robust operational performance and prudent financial management. A key highlight is the company’s ability to service its debt efficiently, with a low Debt to EBITDA ratio of 1.40 times. This indicates manageable leverage and a healthy balance sheet, which is crucial for sustaining growth in the healthcare services sector.
Moreover, the company has shown consistent long-term growth, with operating profit expanding at an impressive annual rate of 60.46%. This growth trajectory reflects effective business strategies and operational efficiencies that bode well for future earnings stability and expansion.
Valuation Perspective
Currently, Suraksha Diagnostic Ltd is assessed with a 'fair' valuation grade. The stock trades at a discount relative to its peers’ historical valuations, which may present an attractive entry point for investors seeking value in the healthcare services sector. The company’s Return on Capital Employed (ROCE) stands at 15.5%, signalling efficient use of capital to generate profits.
Additionally, the Enterprise Value to Capital Employed ratio is 5.5, reinforcing the notion that the stock is reasonably priced given its earnings potential. Despite a modest profit growth of 2% over the past year, the stock has delivered a 17.73% return during the same period, suggesting that market sentiment remains favourable. However, the PEG ratio of 27.2 indicates that investors should monitor valuation multiples carefully as the company continues to grow.
Financial Trend and Recent Performance
The financial trend for Suraksha Diagnostic Ltd is currently positive, supported by recent quarterly results that mark a turnaround after two consecutive negative quarters. As of 05 October 2026, the company reported its highest quarterly net sales at ₹87.65 crores, with Profit Before Tax (excluding other income) reaching ₹15.44 crores, reflecting a 49.2% growth compared to the previous four-quarter average.
Furthermore, the company’s Profit Before Depreciation, Interest, and Taxes (PBDIT) for the quarter hit a record ₹30.44 crores, underscoring operational strength. These figures highlight a recovery in profitability and a solid foundation for sustained growth, which supports the current 'Buy' rating.
Technical Analysis
From a technical standpoint, Suraksha Diagnostic Ltd exhibits a bullish trend. The stock’s price movements over recent months have been positive, with returns of +4.04% over one month, +26.21% over three months, and +41.23% over six months. Year-to-date returns stand at +28.75%, while the one-year return is +15.52%, indicating steady investor confidence and momentum.
Despite a slight dip of -1.41% on the day of analysis, the overall technical indicators suggest that the stock remains in an upward trajectory, supported by strong institutional holdings of 36.7%. Institutional investors typically possess greater analytical resources, and their significant stake often signals confidence in the company’s fundamentals and growth prospects.
Implications for Investors
For investors, the 'Buy' rating on Suraksha Diagnostic Ltd implies that the stock is expected to outperform the market or its sector peers over the medium term. The combination of good quality, fair valuation, positive financial trends, and bullish technicals provides a compelling case for considering this stock as part of a diversified portfolio.
However, investors should remain mindful of the company’s PEG ratio and monitor ongoing quarterly results to ensure that growth momentum is sustained. The healthcare services sector can be sensitive to regulatory changes and market dynamics, so continuous evaluation is advisable.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Summary of Key Metrics as of 05 October 2026
Suraksha Diagnostic Ltd’s current Mojo Score stands at 75.0, reflecting a solid 'Buy' grade. The company’s market capitalisation remains in the microcap segment, which may offer growth potential but also entails higher volatility. The sector focus on healthcare services positions the company in a resilient industry with steady demand.
Stock returns over various periods reinforce the positive outlook: a 1-month gain of 4.04%, 3-month gain of 26.21%, and 6-month gain of 41.23%. The year-to-date return of 28.75% and one-year return of 15.52% further demonstrate consistent performance.
Institutional investors hold a significant 36.7% stake, which often correlates with better governance and strategic oversight. The company’s financial health, operational growth, and valuation metrics collectively justify the current 'Buy' rating.
Conclusion
Suraksha Diagnostic Ltd’s 'Buy' rating by MarketsMOJO, last updated on 01 September 2026, is supported by a strong quality profile, fair valuation, positive financial trends, and bullish technical indicators as of 05 October 2026. Investors looking for exposure in the healthcare services sector may find this stock appealing due to its growth momentum, improving profitability, and reasonable pricing relative to peers.
While the stock has shown commendable returns and operational improvements, ongoing monitoring of financial results and market conditions remains essential. The current rating suggests that Suraksha Diagnostic Ltd is well-positioned to deliver value to shareholders in the near to medium term.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
